Company profile: Silverback Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies, developing ImmunoTAC treatments targeting previously inaccessible disease pathways, and a needle-free, low-dose intranasal epinephrine nasal spray for use as a rescue medication for people with Type 1 severe allergic reactions including anaphylaxis.
Products and services
- ImmunoTAC Therapies: Develops biopharmaceutical ImmunoTAC therapies that target previously inaccessible disease pathways, creating therapeutics directed at hard-to-reach mechanisms
- ImmunoTAC Therapeutic Targeting: Engineers targeted therapeutic approaches for previously inaccessible disease pathways using ImmunoTAC, directing treatments precisely to pathways historically unreachable
- Epinephrine Nasal Spray: Needle-free, low-dose intranasal epinephrine nasal spray used as rescue medication for people with Type 1 severe allergic reactions including anaphylaxis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Silverback Therapeutics
Ernexa
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development of cytokine-based therapies, using mRNA to express reprogramming proteins for allogeneic pluripotent stem cell-derived CAR-T and CAR-NK therapies and to express gene-editing proteins, including UltraSlice, to deactivate, repair, insert, replace, or delete specific DNA sequences, and employing LNP technology, such as ToRNAdo, for efficient and safe delivery of mRNA cargo into human cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ernexa company profile →
Estrella Biopharma
HQ: United States
Website
- Description: Provider of proprietary CD19-Redirected ARTEMIS T-cell therapies for cancer, designed to treat CD19-positive blood cancers with reduced risk of CRS and neurotoxicity. Offerings include a Mark-and-Kill approach using an oncolytic virus to label solid tumors for targeting by ARTEMIS T Cells, EB104 (CD19/CD22) for blood cancers, and EB103 combined with an oncolytic virus for solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Estrella Biopharma company profile →
Medifocus
HQ: United States
Website
- Description: Provider of minimally invasive treatment systems for cancerous and benign tumors and enlarged prostate (BPH), developing and commercializing solutions based on two technology platforms with approximately 100 issued and pending US and international patents.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medifocus company profile →
OncoSynergy
HQ: United States
Website
- Description: Provider of Resistance Mechanism Inhibitors (RMIs) targeting multiple cancer-driving pathways to address resistance, including OS2966, a monoclonal antibody against CD29 to inhibit cancer growth, invasiveness, and resistance. Conducting a Phase 1 trial in recurrent glioblastoma evaluating OS2966 delivered directly to the brain via convection-enhanced delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoSynergy company profile →
Intellikine
HQ: United States
Website
- Description: Provider of discovery and development of orally available small-molecule therapies targeting the PI3K/Akt/mTOR pathway, building a discovery platform to rapidly generate kinase inhibitor drug candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intellikine company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Silverback Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Silverback Therapeutics
2.2 - Growth funds investing in similar companies to Silverback Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Silverback Therapeutics
4.2 - Public trading comparable groups for Silverback Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →